Macrolide and fluoroquinolone resistance in Mycoplasma genitalium isolated from pregnant women in Russia and Belarus | CMAC

Macrolide and fluoroquinolone resistance in Mycoplasma genitalium isolated from pregnant women in Russia and Belarus

Clinical Microbiology and Antimicrobial Chemotherapy. 2024; 26(2):201-207

​ Avchinnikova D.A., Edelstein I.A., Pokusaeva V.N., Rudneva N.S., Sukhanova L.N., Akhmedova A.M., Madzharova O.A., Lapuka M.O., Romanov A.V.
10.36488/cmac.2024.2.201-207
Mycoplasma genitalium pregnant women antimicrobial resistance mutations macrolides fluoroquinolones
Section
Antimicrobial Resistance
Type
Original Article
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2024; 26(2):201-207

Objective.

To study epidemiology of resistance to macrolides and fluoroquinolones in Mycoplasmagenitalium isolated from pregnant women in Russia and Belarus.

Materials and Methods.

A total of 107 M. genitalium DNA samples isolated from pregnant women in Russia (n = 58) and Belarus (n = 49) was included in the study. In order to detect markers of macrolide or fluoroquinolone resistance, polymerase chain reaction in real time with the effect of quenching fluorescence of the probe by a primer was used. Confirmation of mutation type was performed using Sanger sequencing.

Results.

The prevalence of M. genitalium resistance mutations to macrolides in Russia (Tula, Smolensk) and Belarus (Vitebsk, Brest, Minsk) was 3.4% (2⁄58) and 6.1% (3⁄49), respectively. Markers of M. genitalium resistance to fluoroquinolones were detected in 5.2% (3⁄58) of samples from Russia and 8.2% (4⁄49) of samples from Belarus. The most common mutations associated with macrolide resistance were A2059G (n = 4), fluoroquinolone resistance – D84N (n = 3) and S80I (n = 3) (numbering according to E. coli).

Conclusions.

The prevalence of M. genitalium resistance markers isolated in pregnant women highlights a need for regular macrolide and fluoroquinolone resistance surveillance.

Daria A. Avchinnikova

Smolensk State Medical University, Smolensk, Russia

Inna A. Edelstein

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Pokusaeva V.N.

Smolensk State Medical University, Smolensk, Russia

Rudneva N.S.

Tula Regional Clinical Dermatology and Venereology Dispensary, Tula, Russia

Sukhanova L.N.

Tula Regional Clinical Dermatology and Venereology Dispensary, Tula, Russia

Akhmedova A.M.

Tula Regional Clinical Dermatology and Venereology Dispensary, Tula, Russia

Madzharova O.A.

Republican Clinical Medical Center of the Administration of the President of the Republic of Belarus, Minsk, Republic of Belarus

Lapuka M.O.

Brest Regional Dermatology and Venereology Dispensary, Brest, Republic of Belarus

Andrey V. Romanov

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

  • 1. Lis R., Rowhani-Rahbar A., Manhart L.E. Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis. Clin Infect Dis. 2015;61:418-426. DOI: 10.1093/cid/civ312
  • 2. Wiesenfeld H.C., Manhart L.E. Mycoplasma genitalium in women: current knowledge and research priorities for this recently emerged pathogen. J Infect Dis. 2017;216(Suppl. 2):S389-S395. DOI: 10.1093/infdis/jix198
  • 3. Yu J., Zhou Y., Luo H., Su X., Gan T., Wang J., et al. Mycoplasma genitalium infection in the female reproductive system: diseases and treatment. Front Microbiol. 2023;14:1098276. DOI: 10.3389/fmicb.2023.1098276
  • 4. Rekha S., Nooren M., Kalyan S., Mohan M., Bharti M., Monika R., et al. Occurrence of Mycoplasma genitalium in the peritoneal fluid of fertile and infertile women with detailed analysis among infertile women. Microb Pathog. 2019;129:183-186. DOI: 10.1016/j.micpath.2019.02.006
  • 5. Baumann L., Cina M., Egli-Gany D.., Goutaki M., Halbeisen F.S., Lohrer G.R., et al. Prevalence of Mycoplasma genitalium in different population groups: systematic review and meta-analysis. Sex Transm Infect. 2018;94:254-261. DOI: 10.1136/sextrans-2017-053384
  • 6. Workowski K.A., Bachmann L.H., Chan P.A., Johnston C.M., Muzny C.A., Park I., et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187. DOI: 10.15585/mmwr.rr7004a1
  • 7. Stewart J.D., Webb B., Francis M., Graham M., Korman T.M. Should we routinely test for Mycoplasma genitalium when testing for other sexually transmitted infections? Med J Aust. 2020;212(1):30-31. DOI: 10.5694/mja2.50399
  • 8. Clinical recommendations. Normal pregnancy, 2020. Available at: https://cr.minzdrav.gov.ru/recomend/288_1. Accessed December 27, 2023. Russian.
  • 9. Rudneva N.S., Sukhanova L.N., Dolgova T.I., Anisimova N.S., Gushchin A.E. Experience in organizing and conducting screening of pregnant women for the presence of control, administrative sexual intercourse, within the framework of the regional program of the Tula region. Vestnik novyh medicinskih tehnologij. 2015;XXII(4):104111. Russian. DOI: 10.12737/17033
  • 10. Clinical recommendations. Decision Of The Ministry of Health of The Republic of Belarus February 19, 2018 N. 17 On approval of the clinical protocol “Medical observation and provision of medical care to women in obstetrics and gynecology” 2018. Available at: https://minzdrav.gov.by/upload/dadvfiles/КП_акушерство%20и%20гинекология_пост.%20МЗ%20РБ%20от%2019.02.2018%20№17.pdf. Accessed December 27, 2023. Russian.
  • 11. Clinical recommendations. Urogenital diseases caused by Mycoplasma genitalium. 2021. Available at: https://cr.minzdrav.gov.ru/schema/216_1. Accessed December 27, 2023. Russian.
  • 12. Machalek D.A., Tao Y., Shilling H., Jensen J.S., Unemo M., Murray G., et al. Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and metaanalysis. Lancet Infect Dis. 2020;20(11):1302-1314. DOI: 10.1016/S1473-3099(20)30154-7
  • 13. Stafford I., Hummel K., Dunn J., Muldrew K., Berra A., Kravitz E. Retrospective analysis of infection and antimicrobial resistance patterns of Mycoplasma genitalium among pregnant women in the southwestern USA. BMJ Open. 2021;11:e050475. DOI: 10.1136/bmjopen-2021-050475
  • 14. Le Roux M.C., Marcelle M., Mafunise B.E., Ditsele R.M.M. Prevalence and molecular analysis of Mycoplasma genitalium strains isolated from pregnant women at an academic hospital in Pretoria, South Africa. STI and HIV World, Congress Abstracts, Brazil, Rio de Janeiro, July 9-12, 2017. P. A58. DOI: 10.1136/sextrans-2017-053264.145
  • 15. Edelstein I.A., Romanov A.V., Kozlov R.S. Development of a real-time PCR assay for detection of macrolide resistance mutations in Mycoplasma genitalium and its application for epidemiological surveillance in Russia. Microbial Drug Resistance. 2023;29(3):69-77. DOI: 10.1089/mdr.2022.013
  • 16. Kuzmenkov A.Y., Vinogradova A.G., Trushin I.V., Avramenko A.A., Edelstein M.V., Dekhnich A.V., et al. AMRcloud: a new paradigm in monitoring of antibiotic resistance. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2019;21(2):119-124. Russian. DOI: 10.36488/cmac.2019.2.119-124
  • 17. Naicker M., Singh R., van der Westhuizen D., Tinarwo P., Abbai N.S. Lack of resistance to macrolides in Mycoplasma genitalium detected in South African pregnant women. S Afr J Infect Dis. 2021;36(1):209. DOI: 10.4102/sajid.v36i1.209
  • 18. Jonduo M.E., Vallely A.J., Whiley D.M., Riddell M.A., Pomat W., Low N., et al. Mycoplasma genitalium macrolide and fluoroquinolone resistance in pregnant women in Papua New Guinea. Sex Transm Infect 2023;99:71-72. DOI: 10.1136/sextrans-2022-055552
  • 19. Totten A.H., Xiao L., Van Der Pol B., Szychowski J., Subramaniam A., Geisler W.M. Retrospective evaluation of Mycoplasma genitalium prevalence and macrolide resistance in a study cohort of pregnant women in Birmingham, AL, From 1997 to 2001. Sex Transm Dis. 2023;50(10):642644. DOI: 10.1097/OLQ.0000000000001843
  • 20. Eidelshtein I.A., Rudneva N.S., Romanov A.V., Zubareva L.M., Kuzmenkov A.Yu., Kolesnikova E.A. Mycoplasma genitalium: monitoring the spread of mutations associated with resistance to macrolides in Russia. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2022;24(1):52-60. Russian. DOI: 10.36488/cmac.2022.1.52-60
  • 21. Gardette M., Hénin N., Le Roy C., Guiraud J., Touati A., Bébéar C. Clinical performance of three commercial molecular diagnostic assays for the detection of fluoroquinolone resistance-associated mutations in Mycoplasma genitalium. J Clin Microbiol. 2022;60(12):e0113522. DOI: 10.1128/jcm.01135-22
  • 22. Bodiyabadu K., Danielewski J., Garland S.M., Machalek D.A., Bradshaw C.S., Birnie J. Detection of parC gene mutations associated with quinolone resistance in Mycoplasma genitalium: evaluation of a multiplex real-time PCR assay. J Med Microbiol. 2021;70(3):001257. DOI: 10.1099/jmm.0.001257
  • 23. Soni S., Horner P., Rayment M., Pinto-Sander N., Naous N., Parkhouse A., et al. British Association for Sexual Health and HIV national guideline for the management of infection with Mycoplasma genitalium (2018). Int J STD AIDS. 2019;30(10):938-950. DOI: 10.1177/0956462419825948
  • 24. Clinical recommendations. Clinical protocol for diagnosis and treatment of patients with sexually transmitted infections. 2009. Available at: https://clck.ru/37otu8. Accessed January 18, 2024. Russian.
  • 25. Sexuell übertragbare Infektionen (STI) – Beratung, Diagnostik und Therapie AWMF, Germany, 2019. Available at: www.awmf.org/leitlinien/detail/ll/059006. Accessed January 18, 2024.
  • 26. The Australian Government Department of Health. Australian STI management guidelines: Mycoplasma genitalium. Available at: www.sti.guidelines.org.au/sexually-transmissible-infections/mycoplasma-genitalium. Accessed January 18, 2024.
  • 27. Jensen J.S., Cusini M., Gomberg M., Moi H., Wilson J., Unemo M. 2021 European guideline on the management of Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol. 2022;36(5):641-650. DOI: 10.1111/jdv.17972
Views
0 Abstract
0 PDF
0 Crossref citations
Shared